This Cooperative Agreement award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) is funding the development of a "living pharmacy" technology to treat diabetes and obesity in companion animals. The $1,000,000 award to Simmbion LLC, a small disadvantaged business in Baltimore, MD, aims to demonstrate the safety and tolerability of a novel, potentially harmless designer organism that can be injected to control blood glucose and weight gain in cats for up to 12 weeks or longer. This cellular factory platform has the broader potential to enable cost-effective, patient-friendly treatments for chronic diseases with fewer side effects. The project is expected to run from March 2025 to February 2027 and may involve sub-awards.
Generated 4/1/25, 5:14 AM